After Jefferies and JMP Securities gave TELA Bio (NASDAQ: TELA) a Buy rating last month, the company received another Buy, this time from Canaccord Genuity. Analyst Kyle Rose maintained a Buy rating on TELA Bio yesterday and set a price target of $18.00. The company’s shares closed last Tuesday at $12.96.
According to TipRanks.com, Rose is a 4-star analyst with an average return of 5.9% and a 47.6% success rate. Rose covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Obalon Therapeutics, and Alphatec Holdings.
TELA Bio has an analyst consensus of Strong Buy, with a price target consensus of $19.67, implying a 52.2% upside from current levels. In a report issued on June 18, JMP Securities also maintained a Buy rating on the stock with a $24.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.55 and a one-year low of $5.25. Currently, TELA Bio has an average volume of 80.06K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TELA Bio, Inc. is a commercial stage medical technology company. It focuses on designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. TELA Bio was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.
